Heart Attack

Clinical Trial Finder

Many patients with heart disease are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY 1142524 in Patients After Acute Myocardial Infarction With Left-ventricular Dysfunction

Condition:   Myocardial Infarction
Interventions:   Drug: BAY1142524;   Drug: Placebo
Sponsor:   Bayer
Not yet recruiting - verified October 2016

Italian Multi-center Registry of Self-apposing Coronary Stent in Patients With STEMI

Condition:   ST Segment Elevation Myocardial Infarction
Intervention:   Device: STENTYS Xposition S
Sponsor:   UOSD Emodinamica Diagnostica e Interventistica
Recruiting - verified November 2016

Diffusion MRI in Heart Failure

Conditions:   Heart Failure;   Myocardial Infarction;   Left Ventricular Hypertrophy
Intervention:   Device: Diffusion Tensor MRI (DTI)
Sponsor:   Massachusetts General Hospital
Not yet recruiting - verified November 2016

Randomized Comparison of Cangrelor, Tirofiban and Prasugrel in Patients With STEMI Referred for Primary PCI.

Conditions:   Coronary Artery Disease;   STEMI - ST Elevation Myocardial Infarction
Interventions:   Drug: Cangrelor;   Drug: Tirofiban;   Drug: Prasugrel
Sponsor:   University Hospital Inselspital, Berne
Not yet recruiting - verified November 2016

Effect of DLBS1033 After Primary PCI in Patients With STE-ACS

Condition:   ST Elevation Myocardial Infarction
Interventions:   Drug: DLBS1033;   Drug: Placebo;   Drug: Standard therapy
Sponsors:   Dexa Medica Group;   Binawaluya Cardiac Hospital, Jakarta
Recruiting - verified November 2016

Time Gain in the Diagnosis Myocardial Infarction by Troponin Point of Care Testing in the Emergency Room

Conditions:   Non STEMI;   Angina Pectoris;   Angina, Stable;   Angina, Unstable;   Angina, Prinzmetal's
Interventions:   Device: Laboratory based troponin test;   Device: Point of care based troponin test 1;   Device: Point of care based troponin test 2
Sponsor:   Ziekenhuis Oost-Limburg
Not yet recruiting - verified November 2016

PPARGC1β and CNTN4 Genotype Aspirin Study

Condition:   Cardiovascular Diseases
Intervention:   Drug: Aspirin
Sponsor:   Royal College of Surgeons, Ireland
Recruiting - verified November 2016

The Vital Signs to Identify, Target, and Assess Level (VITAL) Care Study III

Conditions:   Cardiac Arrest;   Renal Failure;   Respiration Failure;   Myocardial Infarction;   Severe Sepsis
Intervention:   Device: Automatic RR Measurement
Sponsor:   Philips Healthcare
Recruiting - verified November 2016

Rivaroxaban or Aspirin for Biological Aortic Prosthesis

Conditions:   Aortic Stenosis;   Aortic Regurgitation;   Thrombosis
Interventions:   Drug: Rivaroxaban 10 MG;   Drug: Aspirin
Sponsors:   Christian Torp-Pedersen;   Aalborg Universitetshospital;   Aarhus University Hospital;   Odense University Hospital;   Rigshospitalet, Denmark
Not yet recruiting - verified November 2016

Trial of MiStent Compared to Xience in Japan

Condition:   Coronary (Artery); Disease
Interventions:   Device: MiStent (MT005) Coronary Artery Stent;   Device: Xience Coronary Artery Stent
Sponsors:   Micell Technologies;   Cardialysis BV;   ClinLogix. LLC
Recruiting - verified November 2016

Radiation Dose Optimization in Diffuse Large B- Cell Lymphoma.

Condition:   NonHodgkin Lymphoma
Interventions:   Radiation: Standard Arm;   Radiation: Experimental Arm
Sponsor:   Tata Memorial Hospital
Recruiting - verified December 2016

Quantitative Coronary Angiography Versus Intravascular Ultrasound GUIDancE for Drug-Eluting Stent Implantation

Conditions:   Coronary Disease;   Coronary Stenoses
Interventions:   Device: quantitative coronary angiography guided coronary intervention with everolimus-eluting stent or zotarolimus-eluting stent;   Device: intravascular ultrasound guided coronary intervention with everolimus-eluting stent or zotarolimus-eluting stent
Sponsors:   CHEOL WHAN LEE, M.D., Ph.D;   CardioVascular Research Foundation, Korea
Not yet recruiting - verified November 2016

Study of Major Cardiovascular Events in Patients With Nonvalvular Atrial Fibrillation Treated With Rivaroxaban

Condition:   Atrial Fibrillation
Intervention:   Drug: Rivaroxaban (Xarelto, BAY59-7939)
Sponsors:   Bayer;   Janssen Research & Development, LLC
Not yet recruiting - verified November 2016

Innovation Research of Differentiation and Treatment Methods Based on CHD Phlegm and Blood Stasis Syndrome

Condition:   Coronary Heart Disease
Intervention:  
Sponsor:   Jingqing Hu
Recruiting - verified November 2016

Erythrocyte Transfusion Based on the Measurement of Central Venous Oxygen Saturation in Postoperative Cardiac Surgery

Condition:   Cardiac Surgery
Intervention:   Other: SVO2 group / control group
Sponsor:   Centre Hospitalier Universitaire, Amiens
Not yet recruiting - verified November 2016

Diagnostic Accuracy of On-line Quantitative Flow Ratio

Condition:   Coronary Artery Disease
Intervention:   Other: QFR (observational)
Sponsor:   Aarhus University Hospital Skejby
Recruiting - verified November 2016

Methylnaltrexone as a Method to Improve Ticagrelor Uptake in Morphine Treated STEMI Patients

Conditions:   STEMI;   Morphine;   Ticagrelor;   Methylnaltrexone
Interventions:   Drug: Methylnaltrexone bromide (Relistor®).;   Drug: Sodium Chloride 9mg/mL
Sponsor:   Karolinska University Hospital
Recruiting - verified November 2016

Bivalirudin in Acute Myocardial Infarction

Condition:   Acute Myocardial Infarction
Interventions:   Drug: Bivalirudin;   Drug: heparin
Sponsor:   Shenzhen Salubris Pharmaceuticals Co., Ltd.
Recruiting - verified November 2016

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects With Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Condition:   Anemia in Subjects With DD-CKD
Interventions:   Drug: vadadustat;   Drug: darbepoetin alfa
Sponsor:   Akebia Therapeutics
Recruiting - verified November 2016

Safety and Efficacy Study of the Amaranth Medical MAGNITUDE Bioresorbable Drug-Eluting Coronary Stent (RENASCENT III)

Conditions:   Coronary Artery Disease;   Myocardial Ischemia
Intervention:   Device: AmM MAGNITUDE Bioresorbable Drug-Eluting Coronary Scaffold
Sponsor:   Amaranth Medical Inc.
Recruiting - verified November 2016

The Box: Using Smart Technology to Improve One-year Outcome of Myocardial Infarction Patients

Condition:   Myocardial Infarction
Intervention:   Other: The Box
Sponsor:   Leiden University Medical Center
Recruiting - verified November 2016

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)

Condition:   Anaemia
Interventions:   Drug: Daprodustat;   Drug: Darbepoetin alfa;   Drug: Placebo;   Drug: Iron Therapy
Sponsor:   GlaxoSmithKline
Recruiting - verified December 2016

Efficacy and Safety Study to Evaluate Vadadustat for the Correction of Anemia in Subjects With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Conditions:   Anemia;   Dialysis-dependent Chronic Kidney Disease
Interventions:   Drug: vadadustat;   Drug: Darbepoetin alfa
Sponsor:   Akebia Therapeutics
Recruiting - verified November 2016

Study on the Effect of Influenza Vaccination After Heart Attack on Future Cardiovascular Prognosis

Conditions:   Myocardial Infarction;   Influenza, Human;   Influenza Vaccines;   Heart Failure;   Stroke
Interventions:   Biological: Influenza vaccine;   Biological: Placebo
Sponsors:   Ole Frobert, MD, PhD;   Swedish Heart Lung Foundation;   Sanofi Pasteur, a Sanofi Company;   Uppsala University;   Lytics
Recruiting - verified November 2016

Antiplatelet Therapy in Acute Mild-Moderate Ischemic Stroke

Condition:   Ischemic Stroke
Interventions:   Drug: clopidogrel;   Drug: Aspirin
Sponsor:   General Hospital of Shenyang Military Region
Not yet recruiting - verified November 2016

Diabetes Complication Control in Community Clinics (D4C) Trial

Conditions:   Diabetes;   Hypertension;   Dyslipidemia;   Cardiovascular Disease
Intervention:   Other: Protocol-based integrated care
Sponsors:   Tulane University;   Xiamen University
Recruiting - verified November 2016

Intravascular Ultrasound Prediction of Myocardial Size and Coronary Computed Tomography-Derived Ischemic Burden for Coronary Lesion

Condition:   Coronary Artery Disease
Intervention:   Other: Intravascular Ultrasound, coronary computed tomography angiography
Sponsors:   Asan Medical Center;   Boston Scientific Corporation
Recruiting - verified November 2016

TRANscatheter or SurgIcal Aortic Valve ReplacemenT in All-Comers With Severe Aortic Valve Stenosis

Condition:   Aortic Valve Stenosis
Interventions:   Device: SAPIEN 3;   Procedure: SAVR
Sponsors:   Seung-Jung Park;   CardioVascular Research Foundation, Korea
Withdrawn - verified November 2016

Interest of CARE Rule to Exclude the Hypothesis of an Acute Coronary Syndrome Without Bioassay - ICARE

Condition:   Chest Pain
Intervention:   Other: CARE Rule
Sponsor:   University Hospital, Angers
Recruiting - verified June 2016

Does Vitamin D Supplementation Enhance Resolution of Inflammation After Community-acquired Pneumonia?

Condition:   Pneumonia
Interventions:   Dietary Supplement: Vitamin D3 supplementation;   Biological: Peripheral blood and induced sputum sampling;   Radiation: Chest computerised tomography (CT) scans;   Other: Symptom questionnaire;   Other: Placebo
Sponsor:   Queen Mary University of London
Not yet recruiting - verified June 2016

Controlling And Lowering Blood Pressure With the MobiusHDTM Device

Condition:   Hypertension
Interventions:   Device: MobiusHD;   Other: Sham Implantation
Sponsor:   Vascular Dynamics, Inc.
Not yet recruiting - verified November 2016

Effect of Lipoprotein(a) Elimination by Lipoprotein Apheresis on Cardiovascular Outcomes

Condition:   Lipoprotein Types--Lp System Lp(A) Hyperlipoproteinemia
Intervention:  
Sponsors:   Technische Universität Dresden;   Kaneka Pharma Europe N.V., Triomflaan 173,1160 Brussels, Belgium
Recruiting - verified November 2016

Paced Electrocardiogram Requiring Fast Emergent Coronary Therapy (PERFECT) Study

Condition:   Acute Myocardial Infarction
Intervention:  
Sponsor:   Hennepin County Medical Center, Minneapolis
Recruiting - verified November 2016

Genomic Responses of Human Immune and Non-Immune Cells to Glucocorticoids

Condition:   Normal Physiology
Interventions:   Drug: Solu-Medrol (methylprednisolone sodium succinate);   Drug: Topical methylprenisolone 0.1%
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified July 2016

Reduced Immunogenicity Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma

Condition:   Mesothelioma
Intervention:   Drug: LMB-100
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified September 2016

Safety and Feasibility of Intracoronary Hypothermia in Acute Myocardial Infarction

Condition:   Myocardial Infarction
Intervention:   Other: intracoronary infusion with saline on 22 and 4°C
Sponsor:   Catharina Ziekenhuis Eindhoven
Completed - verified November 2016

Enhanced Detection of Underlying, Covert ATrial Fibrillation Using 7-day Holter Electrocardiogram in Patients With Embolic Stroke of Undetermined Source

Condition:   Stroke
Intervention:  
Sponsor:   National Cerebral and Cardiovascular Center
Recruiting - verified December 2016

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

Conditions:   Anemia;   Non-dialysis-dependent Chronic Kidney Disease
Interventions:   Drug: vadadustat;   Drug: darbepoetin alfa
Sponsor:   Akebia Therapeutics
Recruiting - verified November 2016

EXpanded CELL ENdocardiac Transplantation (EXCELLENT)

Condition:   Acute Myocardial Infarction
Interventions:   Drug: PROTHERACYTES;   Device: Standard of Care (Percutaneous Transluminal Coronary Angioplasty and stent(s) implantation)
Sponsor:   CellProthera
Recruiting - verified October 2016

Efficacy and Safety Study to Evaluate Vadadustat for the Correction of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

Conditions:   Anemia;   Non-dialysis-dependent Chronic Kidney Disease
Interventions:   Drug: vadadustat;   Drug: darbepoetin alfa
Sponsor:   Akebia Therapeutics
Recruiting - verified November 2016

Randomized Comparison of DCB for the Treatment of Superficial Femoral and Popliteal Peripheral Artery Disease

Conditions:   Angioplasty, Balloon;   Catheterization, Peripheral;   Popliteal Artery;   Femoral Artery
Interventions:   Device: IN.PACT drug coated balloon;   Device: Lutonix drug coated balloon
Sponsor:   Seung-Whan Lee, M.D., Ph.D.
Recruiting - verified November 2016

Clinical Performance Evaluation of AQT90 FLEX TnI and TnT

Condition:   Myocardial Infarction
Intervention:  
Sponsor:   Radiometer Medical ApS
Recruiting - verified November 2016

AZD9668, an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation

Conditions:   Chronic Graft vs Host Disease;   Chronic Graft-Versus-Host-Disease;   Bronchiolitis Obliterans Syndrome
Intervention:   Drug: AZD9668
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified September 2016

Clinical Study of the Aorta-femoral Bypass and Hybrid Intervention and the Iliac Arteries With Stenting and Plasty of the Common Femoral Artery Effectiveness in Patients With the Iliac Segment and Femoral Artery Occlusive Disease (TASC C, D)

Condition:   Atherosclerosis of the Peripheral Arteries
Interventions:   Procedure: Hybrid Intervention;   Procedure: Aorta femoral Bypass
Sponsor:   Meshalkin Research Institute of Pathology of Circulation
Active, not recruiting - verified November 2016

Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes

Condition:   Transcatheter Aortic Valve Replacement
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Acetylsalicylic acid;   Drug: Clopidogrel
Sponsors:   Bayer;   Janssen Research & Development, LLC
Recruiting - verified November 2016

Effect of Simvastatin Withdrawal on Ocular Endothelial Function

Condition:   Healthy
Interventions:   Device: Dynamic Vessel Analyzer (DVA);   Device: Laser Doppler Velocimetry (LDV);   Drug: Simvastatin;   Other: Placebo
Sponsor:   Medical University of Vienna
Not yet recruiting - verified December 2016

Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE)

Condition:   Venous Thromboembolism
Intervention:   Drug: Rivaroxaban (Xarelto, BAY59-7939)
Sponsor:   Bayer
Recruiting - verified November 2016

Prospective Record Of the Use of Dabigatran in Patients With Acute Stroke or TIA

Conditions:   Brain Ischemia With Non-valvular Atrial Fibrillation;   Transient Ischemic Attack With Non-valvular Atrial Fibrillation
Intervention:  
Sponsor:   University Hospital, Essen
Recruiting - verified November 2016

The Use of Aging Biomarkers to Predict Adverse Outcomes After Cardiac Surgery

Condition:   Coronary Artery Disease
Intervention:  
Sponsors:   HealthSpan Dx;   Duke University
Completed - verified November 2016

Assessment of the GORE® EXCLUDER® Conformable AAA Endoprosthesis in the Treatment of Abdominal Aortic Aneurysms

Condition:   Aortic Aneurysm, Abdominal
Intervention:   Device: GORE® EXCLUDER® Conformable AAA Endoprosthesis
Sponsor:   W.L.Gore & Associates
Not yet recruiting - verified November 2016

Impact of the Obstructive Sleep Apnea Syndrome (OSAS) on the Ventricular Remodeling After Acute Myocardial Infarction

Condition:   Recent Acute Myocardial Infarction
Interventions:   Other: Without Obstructive Sleep Apnea (syndrome);   Other: Mild or moderate Obstructive Sleep Apnea (syndrome);   Other: Severe Obstructive Sleep Apnea (syndrome);   Device: CPAP
Sponsor:   University Hospital, Montpellier
Recruiting - verified November 2016

Trial of a Novel Paclitaxel-coated Balloon With Citrate Excipient for Restenosis in -Limus Analogue DES

Condition:   Coronary Restenosis
Intervention:   Device: PCB
Sponsor:   Deutsches Herzzentrum Muenchen
Active, not recruiting - verified November 2016

The Development and Evaluation of a Brief CFT Intervention for Trauma

Conditions:   Trauma;   PTSD
Intervention:   Other: Compassion Focused Therapy (self-practice)
Sponsors:   University of Lincoln;   University of Nottingham
Recruiting - verified December 2016

Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults

Conditions:   HIV Infections;   Cardiovascular Diseases
Interventions:   Drug: Pitavastatin;   Drug: Placebo
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Heart, Lung, and Blood Institute (NHLBI);   Kowa Pharmaceuticals America, Inc.
Recruiting - verified November 2016

Revascularization With BVS or CABG in Patients With Advanced CAD

Condition:   Multivessel Coronary Artery Disease
Interventions:   Procedure: PCI -BVS;   Procedure: CABG
Sponsor:   Poznan University of Medical Sciences
Terminated - verified November 2016

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Conditions:   Myelodysplastic Syndrome;   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma;   Acute Leukemia;   Multiple Myeloma
Interventions:   Biological: Rituximab;   Drug: Conditioning Chemotherapy;   Drug: TMS;   Drug: FLAG;   Drug: EPOCH-F;   Procedure: Hematopoietic Stem Cell Transplant;   Drug: Palifermin
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified October 2016

Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)

Condition:   Stroke
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Aspirin (Acetylsalicylic acid, BAY1019036);   Other: Rivaroxaban-Placebo;   Other: Aspirin-Placebo
Sponsors:   Bayer;   Janssen, LP;   Hamilton Health Sciences Cooperation, Population Health Research Institute
Recruiting - verified November 2016

Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction (UPSTREAM): An ED-Based Clinical Registry

Condition:   Acute Coronary Syndromes
Intervention:   Other: Non-Interventional Study
Sponsor:   AstraZeneca
Recruiting - verified November 2016

Berlin Atrial Fibrillation Registry

Conditions:   Acute Ischemic Stroke;   Atrial Fibrillation
Intervention:  
Sponsors:   Charite University, Berlin, Germany;   Center for Stroke Research Berlin;   Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
Active, not recruiting - verified November 2016

AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study.

Condition:   Polycythemia Vera
Interventions:   Drug: Pegylated-Proline-interferon alpha-2b;   Drug: Best available therapy (BAT)
Sponsors:   AOP Orphan Pharmaceuticals AG;   PharmaEssentia (Co-Sponsor for USA)
Active, not recruiting - verified November 2016

Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)

Conditions:   Atrial Fibrillation;   Percutaneous Coronary Intervention
Interventions:   Drug: Dabigatran Etexilate 110mg;   Drug: Warfarin 3mg;   Drug: Aspirin;   Drug: Dabigatran Etexilate 150mg;   Drug: Clopidogrel or Ticagrelor;   Drug: Clopidogrel or Ticagrelor;   Drug: Warfarin 5mg;   Drug: Clopidogrel or Ticagrelor;   Drug: Warfarin 1mg
Sponsor:   Boehringer Ingelheim
Recruiting - verified October 2016

Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM)

Conditions:   Lung Cancer;   Breast Cancer;   Prostate Cancer;   Tumors (Others);   Ovarian Cancer
Intervention:   Biological: MVA-brachyury- TRICOM
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting - verified September 2016

Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia

Condition:   Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)
Interventions:   Drug: Epanova® (omega-3 carboxylic acids);   Drug: corn oil control
Sponsors:   AstraZeneca;   Cleveland Clinic Coordinating Center for Clinical Research (C5R);   Quintiles, Inc.
Recruiting - verified November 2016

A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients

Conditions:   Heart Failure;   Respiratory Insufficiency;   Stroke Acute;   Infectious Diseases;   Rheumatic Diseases
Interventions:   Drug: Rivaroxaban, 10 mg;   Drug: Rivaroxaban, 7.5 mg;   Drug: Placebo
Sponsor:   Janssen Research & Development, LLC
Recruiting - verified November 2016

Genetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

Conditions:   Malignant Pericardial Effusion;   Malignant Pleural Effusion;   Recurrent Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions:   Other: cytology specimen collection procedure;   Procedure: therapeutic procedure;   Drug: targeted therapy;   Other: laboratory biomarker analysis
Sponsors:   Fox Chase Cancer Center;   National Cancer Institute (NCI)
Terminated - verified November 2016

Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)

Conditions:   Pulmonary Embolism;   Thromboembolism;   Thrombosis;   Venous Thrombosis;   Venous Thromboembolism
Interventions:   Drug: BAY 59-7939;   Drug: BAY 59-7939;   Drug: ASA
Sponsor:   Bayer
Completed - verified November 2016

A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Ticagrelor 60 mg;   Drug: Ticagrelor placebo
Sponsor:   AstraZeneca
Active, not recruiting - verified November 2016

Essential Hypotension and Adaptability Registry

Conditions:   Blood Pressure;   Depression;   Panic Attack;   Fibromyalgia;   POTS;   Inappropriate Sinus Tachycardia;   Coronary Heart Disease;   Acute Coronary Syndrome (ACS);   Acute Myocardial Infarction (AMI);   Cerebrovascular Disease (CVD);   Transient Ischemic Attack (TIA);   Atrial Fibrillation;   Diabetes Mellitus;   Cancer;   Systolic Heart Failure;   Diastolic Heart Failure;   Chronic Fatigue Syndrome;   Syncope;   Vasovagal Syncope
Intervention:  
Sponsor:   CES University
Recruiting - verified November 2016

Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin;   Drug: Placebo
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Recruiting - verified November 2016

The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

Condition:   Cardiovascular Disease
Interventions:   Drug: bococizumab (PF-04950615);   Drug: Placebo
Sponsor:   Pfizer
Active, not recruiting - verified November 2016

Ticagrelor for PCI Post Thrombolysis

Condition:   Acute Myocardial Infarction
Interventions:   Drug: Ticagrelor;   Drug: Clopidogrel
Sponsors:   St. Michael's Hospital, Toronto;   Prairie Vascular Research Inc.
Completed - verified November 2016

Searching for Explanations for Cryptogenic Stroke in the Young: Revealing the Etiology, Triggers, and Outcome

Conditions:   Brain Infarction;   Ischemic Stroke;   Thrombosis;   Foramen Ovale, Patent
Intervention:  
Sponsors:   SECRETO Study Consortium;   Finnish Medical Foundation;   Helsinki University Central Hospital;   Academy of Finland;   Göteborg University
Recruiting - verified November 2016

A Toolbox Approach to Obesity Treatment in Primary Care

Condition:   Obesity
Interventions:   Behavioral: Commercial weight loss program;   Behavioral: Colorado Weigh;   Dietary Supplement: Meal replacements;   Drug: Obesity pharmacotherapy;   Behavioral: Recreation center passes
Sponsor:   Denver Health and Hospital Authority
Active, not recruiting - verified November 2016

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: Linagliptin
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Active, not recruiting - verified November 2016

A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure

Conditions:   Heart Failure;   Coronary Artery Disease
Interventions:   Drug: Rivaroxaban;   Drug: Placebo;   Other: Standard of care for heart failure and coronary artery disease
Sponsors:   Janssen Research & Development, LLC;   Bayer
Recruiting - verified November 2016

ALdosterone Antagonist Chronic HEModialysis Interventional Survival Trial

Condition:   End Stage Renal Failure on Dialysis
Interventions:   Drug: Spironolactone;   Drug: Placebo
Sponsors:   University Hospital, Brest;   Central Hospital, Nancy, France;   Institut National de la Santé Et de la Recherche Médicale, France
Recruiting - verified November 2016

Randomized Endo-Vein Graft Prospective

Condition:   Coronary Artery Bypass Grafting
Intervention:   Procedure: Vein Harvesting Procedures
Sponsor:   VA Office of Research and Development
Recruiting - verified November 2016

5 Year Observation of Patients With PORTICO Valves

Condition:   Aortic Valve Stenosis
Interventions:   Device: St Jude Medical Portico replacement aortic valve;   Procedure: Transcatheter Aortic Valve Implant
Sponsor:   St. Jude Medical
Recruiting - verified November 2016

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

Condition:   Dyslipidemia
Interventions:   Biological: Evolocumab (AMG 145);   Other: Placebo;   Drug: Effective statin therapy
Sponsor:   Amgen
Completed - verified November 2016

MACCE in Hospitalized Patients With Community-acquired Pneumonia

Condition:   Community-acquired Pneumonia
Intervention:  
Sponsor:   University of Roma La Sapienza
Recruiting - verified November 2016

The Dutch Asymptomatic Mitral Regurgitation Trial

Conditions:   Heart; Disease, Mitral(Valve);   Diseases of Mitral Valve;   Mitral Valve Insufficiency
Interventions:   Other: Watchful waiting;   Procedure: Early mitral valve repair
Sponsors:   UMC Utrecht;   Leiden University Medical Center;   The Interuniversity Cardiology Institute of the Netherlands;   WCN, Dutch Network for Cardiovascular Research
Terminated - verified November 2016

ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

Condition:   Acute Coronary Syndrome
Interventions:   Drug: alirocumab;   Drug: Placebo
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified November 2016

Intracoronary Stenting and Angiographic Results: Optimizing Treatment of Drug Eluting Stent In-Stent Restenosis 4

Conditions:   Restenosis;   Stable Angina Pectoris;   Acute Coronary Syndrome
Interventions:   Device: Paclitaxel Eluting Balloon + Scoring Balloon;   Device: Paclitaxel Eluting Balloon
Sponsors:   Deutsches Herzzentrum Muenchen;   Biotronik AG
Completed - verified November 2016

Cardiovascular Inflammation Reduction Trial

Condition:   Cardiovascular Disease
Interventions:   Drug: Methotrexate;   Drug: Placebo
Sponsors:   Brigham and Women's Hospital;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified November 2016

Cancer Vaccine Targeting Brachyury Protein in Tumors

Conditions:   Neoplasms;   Malignant Solid Tumors;   Colon Neoplasms;   Adenocarcinoma
Intervention:   Biological: GI-6301 (Yeast Brachyury Vaccine)
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting - verified September 2016

Clinical Trial on the Use of 25-OH -D Vitamin in Haemodialysis Patients

Condition:   Chronic Renal Failure
Intervention:   Drug: 25-OH-D vitamin
Sponsors:   Italian Society of Nephrology;   Società Italiana di Nefrologia
Terminated - verified November 2016

Hyper-CVAD and Ponatinib in Ph-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)

Condition:   Leukemia
Interventions:   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Dexamethasone;   Drug: Ponatinib;   Drug: G-CSF (Filgrastim);   Drug: Rituximab;   Drug: Methotrexate;   Drug: Cytarabine;   Drug: Solu-medrol ( Methyl Prednisolone);   Drug: Citrovorum (Leucovorin);   Drug: Prednisone;   Drug: Pegfilgrastim (Neulasta)
Sponsors:   M.D. Anderson Cancer Center;   Ariad Pharmaceuticals
Recruiting - verified November 2016

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Condition:   Atherosclerosis
Interventions:   Drug: Canakinumab;   Drug: Placebo
Sponsor:   Novartis Pharmaceuticals
Active, not recruiting - verified November 2016

Post-authorization Safety Study of Etoricoxib and Other Anti-inflammatory Therapies in European Patients With Ankylosing Spondylitis (MK-0663-163)

Condition:   Ankylosing Spondylitis
Intervention:  
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting - verified November 2016

To Investigate the Role of Upstream High Dose Statin in STEMI

Condition:   Acute Myocardial Infarction
Interventions:   Drug: Atorvastatin calcium;   Drug: Inactive Placebo
Sponsors:   The Western Pennsylvania Hospital;   West Penn Allegheny Health System
Completed - verified November 2016

CANVAS - CANagliflozin cardioVascular Assessment Study

Conditions:   Diabetes Mellitus, Type 2;   Cardiovascular Diseases;   Risk Factors
Interventions:   Drug: Canagliflozin (JNJ-28431754);   Drug: Placebo
Sponsors:   Janssen Research & Development, LLC;   The George Institute for Global Health, Australia
Active, not recruiting - verified November 2016

Molecular and Morphologic Characterization of Circulating Endothelial Cells

Condition:   Acute Myocardial Infarction
Intervention:  
Sponsor:   Scripps Translational Science Institute
Enrolling by invitation - verified November 2016

The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Darapladib 160 mg;   Drug: Placebo;   Other: Standard Therapy
Sponsors:   GlaxoSmithKline;   The TIMI Study Group
Completed - verified November 2016

Efficacy Study of Paclitaxel-eluting Balloon, -Stent vs. Plain Angioplasty for Drug-eluting Stent Restenosis

Conditions:   Heart Disease;   Ischemia;   Restenosis
Interventions:   Device: Taxus stent;   Device: SeQuent Please;   Device: Conventional Balloon Catheter
Sponsor:   Deutsches Herzzentrum Muenchen
Completed - verified November 2016

The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial

Condition:   Atherosclerosis
Interventions:   Drug: Darapladib;   Drug: Placebo
Sponsor:   GlaxoSmithKline
Completed - verified November 2016

The Effect of Glucose-Insulin-Potassium Infusion in Patients Undergoing Cardiac Surgery

Conditions:   Aortic Stenosis;   Coronary Heart Disease;   Heart Failure
Interventions:   Drug: Glucose-insulin-potassium;   Drug: Placebo
Sponsor:   Christoph Ellenberger
Completed - verified November 2016

Genomic Investigation of Cardiovascular Diseases

Conditions:   Coronary Artery Disease;   Myocardial Infarction;   Atrial Fibrillation;   Aortic Stenosis;   Mitral Regurgitation;   Idiopathic Cardiomyopathy
Intervention:  
Sponsor:   Scripps Translational Science Institute
Active, not recruiting - verified November 2016

Multicenter Study of Immunoadsorption in Dilated Cardiomyopathy

Condition:   Dilated Cardiomyopathy
Interventions:   Device: protein A immunoadsorption;   Device: pseudo-immunoadsorption
Sponsors:   University Medicine Greifswald;   Krupp von Bohlen und Halbach-Foundation, Essen, Germany;   ENDI-Foundation, Bad Homburg, Germany;   Bristol-Myers Squibb
Recruiting - verified November 2016

Genetic Risk Factors Associated With Antiphospholipid Antibody Syndrome

Condition:   Antiphospholipid Syndrome
Intervention:  
Sponsor:   Duke University
Recruiting - verified July 2016

Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignances

Conditions:   Immunosuppression;   Leukemia
Intervention:   Device: SOLEX 300i Stem Cell Selection
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified November 2016

NT-proBNP and New Biomarkers in Patients With Dyspnea and/or Peripheral Edema

Conditions:   Dyspnea;   Peripheral Edema
Intervention:  
Sponsor:   Universitätsmedizin Mannheim
Active, not recruiting - verified November 2016

Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome

Conditions:   Mycosis Fungoides;   Sezary Syndrome
Intervention:   Drug: Campath-1H
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2016

Technical Development of Cardiovascular Magnetic Resonance Imaging

Condition:   Cardiovascular Disease
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified November 2016

Diagnosis of Pheochromocytoma

Condition:   Pheochromocytoma
Intervention:  
Sponsor:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified November 2016

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

Conditions:   Atherosclerosis;   Cardiovascular Diseases;   Hypercholesterolemia;   Hypertension;   Diabetes Mellitus, Type 2;   Diabetes Mellitus;   Coronary Disease
Interventions:   Drug: Anti-hyperglycemic Agents;   Drug: Anti-hypertensive Agents;   Drug: Blinded fenofibrate or placebo plus simvastatin
Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   National Institute on Aging (NIA);   National Eye Institute (NEI);   Centers for Disease Control and Prevention
Completed - verified November 2014